Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging

Radiology

Volumn 264, Issue 1, 2012, Pages 225-233

  Tourdias, Thomas ^a   Roggerone, Steṕhanie ^b   Filippi, Massimo ^c   Kanagaki, Mitsunori ^d   Rovaris, Marco ^e   Miller, David H ^f   Petry, Klaus G ^a   Brochet, Bruno ^a   Pruvo, Jean Pierre ^g   Radüe, Ernst Wilhelm ^h   Dousset, Vincent ^a  

^a University Bordeaux 2   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d KYOTO UNIVERSITY   (Japan)

^e IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERATE MEGLUMINE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPNEA; ERYTHEMA; FOLLOW UP; HUMAN; IMAGE QUALITY; LIMB PAIN; LONGITUDINAL STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URTICARIA;

ADULT; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DEXTRANS; DISABILITY EVALUATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MEGLUMINE; MIDDLE AGED; MULTIPLE SCLEROSIS; ORGANOMETALLIC COMPOUNDS; PHENOTYPE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 84862649396     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111416     Document Type: Article

References (32)

1. Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology 2011;259(3): 659-681.
2. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58(6):840-846. (Pubitemid 41746873)
3. Barkhof F, Rocca M, Francis G, et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 2003;53(6):718-724. (Pubitemid 36622508)
4. Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008;255(10):1449-1463.
5. Smith JJ, Sorensen AG, Thrall JH. Biomarkers in imaging: realizing radiology's future. Radiology 2003;227(3):633-638. (Pubitemid 36583016)
6. Dousset V, Ballarino L, Delalande C, et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol 1999;20(2):223-227. (Pubitemid 30418702)
7. Floris S, Blezer EL, Schreibelt G, et al. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 2004;127(Pt 3):616-627. (Pubitemid 38295477)
8. Stoll G, Bendszus M. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging. Neuroscience 2009;158(3):1151-1160.
9. Dousset V, Brochet B, Deloire MS, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol 2006;27(5):1000-1005. (Pubitemid 44897675)
10. Vellinga MM, Oude Engberink RD, Seewann A, et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 2008;131(Pt 3):800-807. (Pubitemid 351294725)
11. Sigovan M, Boussel L, Sulaiman A, et al. Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model. Radiology 2009;252(2):401-409.
12. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6(10): 903-912. (Pubitemid 47405002)
13. Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and bloodbrain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007;33(1):86-98. (Pubitemid 46090313)
14. Bradl M, Lassmann H. Progressive multiple sclerosis. Semin Immunopathol 2009; 31(4):455-465.
15. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995;32(2):121-182.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444-1452. (Pubitemid 14237132)
17. Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60(4):640-646. (Pubitemid 36246083)
18. Dousset V, Gomez C, Petry KG, Delalande C, Caille JM. Dose and scanning delay using USPIO for central nervous system macrophage imaging. MAGMA 1999;8(3): 185-189. (Pubitemid 29436571)
19. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/ short-TE (T1-weighted) spin-echo images. Neurology 1995;45(9):1684-1690.
20. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2):292-302.
21. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129(Pt 3):606-616. (Pubitemid 43278223)
22. Lutz AM, Weishaupt D, Persohn E, et al. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics. Radiology 2005;234(3):765-775. (Pubitemid 40250820)
23. Vellinga MM, Vrenken H, Hulst HE, et al. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normalappearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. J Magn Reson Imaging 2009;29(4):774-779.
24. Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ. Is inflammation important in early PPMS? a longitudinal MRI study. J Neurol Neurosurg Psychiatry 2005;76(9): 1255-1258. (Pubitemid 41208379)
25. Soon D, Tozer DJ, Altmann DR, Tofts PS, Miller DH. Quantification of subtle bloodbrain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes. Mult Scler 2007;13(7):884-894. (Pubitemid 351540860)
26. Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72(8):705-711.
27. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007;20(3):269-274. (Pubitemid 46743107)
28. Mikita J, Dubourdieu-Cassagno N, Deloire MS, et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis: amelioration of clinical status by M2 activated monocyte administration. Mult Scler 2011;17(1):2-15.
29. Brochet B, Deloire MS, Touil T, et al. Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE. Neuroimage 2006;32(1):266-274.
30. Bernd H, De Kerviler E, Gaillard S, Bonnemain B. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest Radiol 2009;44(6):336-342.
31. Giesel FL, Mehndiratta A, Essig M. Highrelaxivity contrast-enhanced magnetic resonance neuroimaging: a review. Eur Radiol 2010;20(10):2461-2474.
32. Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64(6):707-713.